Evidence map›Paper›PMID 38613342›Full record

ArticleJournal of cellular and molecular medicine2024

Identification and characterization of novel genetic variants in the first Chinese family of mucopolysaccharidosis IIIC (Sanfilippo C syndrome).

Hongjun Zhao, Lijing Wang, Mengfei Zhang, Huakun Wang, Sizhe Zhang, Junjiao Wu, Yu Tang

Open access · goldAbstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Hongjun ZhaoDepartment of Rheumatology and Immunology, Xiangya Hospital, Central South University, Changsha, China.
Lijing WangNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Mengfei ZhangNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Huakun WangNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Sizhe ZhangNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Junjiao WuDepartment of Rheumatology and Immunology, Xiangya Hospital, Central South University, Changsha, China.
Yu TangNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.ORCID 0000-0001-9709-9614
Central South University · CN

Funding

Hunan Provincial Natural Science Foundation of China 2022JJ40824National Natural Sciences Foundation of China 82271280National Natural Sciences Foundation of China 82301433Scientific Research Project of Hunan Provincial Health Commission B202303070054Xiangya Hospital, Central South University 2021Q04Xiangya Hospital, Central South University 2022LNJJ14Xiangya Hospital, Central South University 2209090550
6 · The paper itself

Abstract

Mucopolysaccharidosis type IIIC (MPS IIIC) is one of inherited lysosomal storage disorders, caused by deficiencies in lysosomal hydrolases degrading acidic mucopolysaccharides. The gene responsible for MPS IIIC is HGSNAT, which encodes an enzyme that catalyses the acetylation of the terminal glucosamine residues of heparan sulfate. So far, few studies have focused on the genetic landscape of MPS IIIC in China, where IIIA and IIIB were the major subtypes. In this study, we utilized whole-exome sequencing (WES) to identify novel compound heterozygous variants in the HGSNAT gene from a Chinese patient with typical MPS IIIC symptoms: c.743G>A; p.Gly248Glu and c.1030C>T; p.Arg344Cys. We performed in silico analysis and experimental validation, which confirmed the deleterious pathogenic nature of both variants, as evidenced by the loss of HGSNAT activity and failure of lysosomal localization. To the best of our knowledge, the MPS IIIC is first confirmed by clinical, biochemical and molecular genetic findings in China. Our study thus expands the spectrum of MPS IIIC pathogenic variants, which is of importance to dissect the pathogenesis and to carry out clinical diagnosis of MPS IIIC. Moreover, this study helps to depict the natural history of Chinese MPS IIIC populations.

Indexed as

MucopolysaccharidosesMucopolysaccharidosis IIIAcetylationAcetyltransferasesChinaEast Asian PeopleHumansAcetyltransferasesHGSNAT protein, humanHGSNATlysosomeMPS IIICmucopolysaccharidosistransmembranevariant

Identifiers

PMID38613342
PMCPMC11015392
OpenAlexW4394787260

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.